These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25200121)

  • 41. Simeprevir approved for hepatitis C virus infection.
    Traynor K
    Am J Health Syst Pharm; 2014 Jan; 71(1):6. PubMed ID: 24352170
    [No Abstract]   [Full Text] [Related]  

  • 42. Guideline: New HCV drugs should go to sickest patients.
    Kuehn BM
    JAMA; 2014 Sep; 312(11):1084-5. PubMed ID: 25226461
    [No Abstract]   [Full Text] [Related]  

  • 43. [Pharmacological properties of simeprevir (SOVRIAD® capsules 100 mg), a new drug for the treatment of hepatitis C, and results of its clinical studies].
    Nagino K; Tsutsumi K; Ishido M; Harada Y
    Nihon Yakurigaku Zasshi; 2015 Feb; 145(2):92-9. PubMed ID: 25747021
    [No Abstract]   [Full Text] [Related]  

  • 44. China rejects patent on hepatitis C drug sofosbuvir.
    Kmietowicz Z
    BMJ; 2015 Jun; 350():h3429. PubMed ID: 26105994
    [No Abstract]   [Full Text] [Related]  

  • 45. Fluctuations in the concentration/dose ratio of calcineurin inhibitors after simeprevir administration in patients with recurrent hepatitis C after liver transplantation.
    Ueda Y; Kaido T; Uemoto S
    Transpl Int; 2015 Feb; 28(2):251-2. PubMed ID: 25174262
    [No Abstract]   [Full Text] [Related]  

  • 46. New drugs 2014, part 2.
    Hussar DA
    Nursing; 2014 Jul; 44(7):26-33; quiz 33-4. PubMed ID: 24905857
    [No Abstract]   [Full Text] [Related]  

  • 47. The good, the bad and the ugly of the new treatments for hepatitis C virus.
    Silva-Vidal KV; Méndez-Sánchez N
    Ann Hepatol; 2014; 13(5):574-5. PubMed ID: 25152995
    [No Abstract]   [Full Text] [Related]  

  • 48. HCV in 2015: Advances in hepatitis C research and treatment.
    Rehermann B
    Nat Rev Gastroenterol Hepatol; 2016 Feb; 13(2):70-2. PubMed ID: 26790365
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacists help patients get started on hepatitis C regimens.
    Traynor K
    Am J Health Syst Pharm; 2017 May; 74(9):e150-e151. PubMed ID: 28438817
    [No Abstract]   [Full Text] [Related]  

  • 50. Advances in Hepatitis C Virus Treatment.
    Lichtenstein GR
    Gastroenterol Hepatol (N Y); 2015 Jul; 11(7):432. PubMed ID: 27118939
    [No Abstract]   [Full Text] [Related]  

  • 51. Hepatitis C: Recent advances.
    Shafran SD; Conly JM
    Can J Infect Dis; 1993 Jul; 4(4):195-7. PubMed ID: 22346447
    [No Abstract]   [Full Text] [Related]  

  • 52. Emerging therapies for hepatitis C.
    Kim DY; Ahn SH; Han KH
    Gut Liver; 2014 Sep; 8(5):471-9. PubMed ID: 25228970
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.
    Yau AH; Yoshida EM
    Can J Gastroenterol Hepatol; 2014 Sep; 28(8):445-51. PubMed ID: 25229466
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.
    Svarovskaia ES; Dvory-Sobol H; Parkin N; Hebner C; Gontcharova V; Martin R; Ouyang W; Han B; Xu S; Ku K; Chiu S; Gane E; Jacobson IM; Nelson DR; Lawitz E; Wyles DL; Bekele N; Brainard D; Symonds WT; McHutchison JG; Miller MD; Mo H
    Clin Infect Dis; 2014 Dec; 59(12):1666-74. PubMed ID: 25266287
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Simeprevir for the treatment of hepatitis C virus infection.
    Izquierdo L; Helle F; François C; Castelain S; Duverlie G; Brochot E
    Pharmgenomics Pers Med; 2014; 7():241-9. PubMed ID: 25206310
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sofosbuvir as backbone of interferon free treatments.
    Bourlière M; Oules V; Ansaldi C; Adhoute X; Castellani P
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S212-20. PubMed ID: 25453869
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging treatments for chronic hepatitis C.
    Hayes CN; Chayama K
    J Formos Med Assoc; 2015 Mar; 114(3):204-15. PubMed ID: 25300586
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent advances in the treatment of hepatitis C.
    Dhingra A; Kapoor S; Alqahtani SA
    Discov Med; 2014 Oct; 18(99):203-8. PubMed ID: 25336034
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sofosbuvir: a novel oral agent for chronic hepatitis C.
    Cholongitas E; Papatheodoridis GV
    Ann Gastroenterol; 2014; 27(4):331-337. PubMed ID: 25332066
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies.
    Mangia A; Piazzolla V
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S179-85. PubMed ID: 25458780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.